Along with partner Vertex Pharmaceuticals, it has won regulatory approval for Casgevy, a revolutionary treatment for SCD and beta-thalassemia. Meanwhile, Intellia is partnered with Regeneron ...

It was the first company to receive FDA approval, in December 2023, for Casgevy – a genome-edited cell therapy for sickle-cell disease and another blood disorder, beta thalassaemia. These are ...

Or take Casgevy, the first CRISPR-approved medicine developed by Vertex and CRISPR Therapeutics and approved in December 2023. Critical to the development of the fetal hemoglobin switching ...

CRISPR Therapeutics, a pioneering biotechnology company specializing in gene-editing therapeutics, showcased strong momentum in late 2023 with the approval of Casgevy, its groundbreaking treatment for ...

CRISPR Therapeutics, a pioneering biotechnology company specializing in gene-editing therapeutics, showcased strong momentum in late 2023 with the approval of Casgevy, its groundbreaking treatment ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Eli Lilly has reduced the prices of certain ...

The company made a major breakthrough in late 2023 when its first product, CASGEVY, became the first-ever CRISPR-based therapy to gain FDA approval. CASGEVY targets two blood disorders—sickle ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

In late 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) for sickle cell disease (SCD), marking the world ...